May 14, 2020 4:15 pm EDT Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
Feb 10, 2020 8:30 am EST Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
Dec 18, 2019 3:00 pm EST Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Jul 24, 2019 9:25 am EDT Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Jan 7, 2019 8:39 am EST Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
